Pulmonary administered palmitic-acid modified exendin-4 peptide prolongs hypoglycemia in type 2 diabetic db/db mice

Regulatory Peptides

Volumn 177, Issue 1-3, 2012, Pages 68-72

  Lee, Juho ^a   Lee, Changkyu ^b   Kim, Tae Hyung ^b   Chi, Sang Cheol ^b   Moon, Hyung Ryong ^a   Oh, Kyung Taek ^c   Lee, Eun Seong ^d   Lee, Kang Choon ^b   Youn, Yu Seok ^b  

^a Pusan National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Chung Ang University   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Hypoglycemia; Palmitic acid modified exendin 4; Pulmonary delivery; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; EXENDIN 4; GLUCOSE; PALMITIC ACID MODIFIED EXENDIN 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG UPTAKE; GLUCOSE BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ANIMALS; BLOOD GLUCOSE; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; PALMITIC ACID; PARTICLE SIZE; PEPTIDES; TIME FACTORS; VENOMS;

MUS;

EID: 84862766234     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.04.010     Document Type: Article

References (27)

1. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402-7405.
2. Davidson M.B., Bate G., Kirkpatrick P. Exenatide. Nat Rev Drug Discov 2005, 4:713-714.
3. Göke R., Fehmann H.C., Linn T., Schmidt H., Krause M., Eng J., Göke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993, 268:19650-19655.
4. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
5. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53:2181-2189.
6. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., Egan J.M. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000, 141:1936-1941.
7. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
8. Chae S.Y., Jin C.H., Shin J.H., Son S., Kim T.H., Lee S., Youn Y.S., Byun Y., Lee M.S., Lee K.C. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release 2010, 142:206-213.
9. Patton J.S., Fishburn C.S., Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004, 1:338-344.
10. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007, 6:67-74.
11. Youn Y.S., Lee K.C., Bae Y.H., Na K., Lee E.S. Advanced pulmonary delivery of peptides or proteins using polymeric particles. Delivery technologies for biopharmaceuticals: peptides, proteins, nucleic acids, and vaccines 2009, 228-244. WILEY. L. Jorgensen, H.M. Lielsen (Eds.).
12. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.
13. Chuang V.T., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002, 19:569-577.
14. Chae S.Y., Choi Y.G., Son S., Jung S.Y., Lee D.S., Lee K.C. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release 2010, 144:10-16.
15. Kim H., Lee J., Kim T.H., Lee E.S., Oh K.T., Lee D.H., Park E.S., Bae Y.H., Lee K.C., Youn Y.S. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm Res 2011, 28:2008-2019.
16. Kim H., Park H., Lee J., Kim T.H., Lee E.S., Oh K.T., Lee K.C., Youn Y.S. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials 2011, 32:1685-1693.
17. Kim I., Kim T.H., Ma K., Park E.S., Oh K.T., Lee E.S., Lee K.C., Youn Y.S. A 4-arm polyethylene glycol derivative conjugated with exendin-4 peptide and palmitylamine having dual-function of size-increase and albumin-binding for long hypoglycemic action. Regul Pept 2011, 167:239-245.
18. Kim I., Kim T.H., Ma K., Lee E.S., Kim D., Oh K.T., Lee D.H., Lee K.C., Youn Y.S. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjug Chem 2010, 21:1513-1519.
19. Lee K.C., Chae S.Y., Kim T.H., Lee S., Lee E.S., Youn Y.S. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regul Pept 2009, 152:101-107.
20. Youn Y.S., Kwon M.J., Na D.H., Chae S.Y., Lee S., Lee K.C. Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. J Control Release 2008, 125:68-75.
21. Audouy S.A., van der Schaaf G., Hinrichs W.L., Frijlink H.W., Wilschut J., Huckriede A. Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization. Vaccine 2011, 29:4345-4352.
22. Nauck M.A., Meier J.J. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005, 128:135-148.
23. Baggio L.L., Huang Q., Cao X., Drucker D.J. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology 2008, 134:1137-1147.
24. Kurtzhals P., Havelund S., Jonassen I., Markussen J. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci 1997, 86:1365-1368.
25. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004, 53:2492-2500.
26. Neumiller J.J., Campbell R.K., Wood L.D. A review of inhaled technosphere insulin. Ann Pharmacother 2010, 44:1231-1239.
27. Sung J.C., Pulliam B.L., Edwards D.A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007, 25:563-570.